🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This week, Intellia will be in Miami at the #LeerinkGlobal Biopharma Conference and Barclays Investment Bank 27th Annual Global Healthcare Conference. Join us as Dr. John Leonard takes part in fireside chats at both events. Details below: Leerink: wsw.com/webcast/leerin… Barclays:

Hear from Amyloidosis Research Consortium's Isabelle Lousada on the significance of #AmyloidosisAwarenessMonth. Let’s continue to share stories and educate others on how to recognize the signs. #AmyloidosisAwareness

There are a lot of ways #CRISPR can be applied in medicine. Dr. Jim Januzzi, cardiologist at MassGeneral News walks us through two of the most common ways. Learn more: intelliatx.com/our-science/

$NTLA News: U.S. FDA grants Intellia Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z) for the treatment of #ATTR #amyloidosis with cardiomyopathy. ir.intelliatx.com/news-releases/…

This weekend, members from the Intellia team will be at the American College of Cardiology (American College of Cardiology) Conference in Chicago. Come visit us at Booth 3052 to learn more about Intellia. #ACC25

$NTLA #ATTR Milestone: The first patient has been dosed in Intellia’s Phase 3 MAGNITUDE-2 study of nexiguran ziclumeran (nex-z) for #ATTR with polyneuropathy: ir.intelliatx.com/news-releases/… #CRISPR #GeneEditing

This weekend, the Intellia team will be in Las Vegas at the Consortium of Independent Immunology Clinics (CIIC) Spring Conference presenting a poster about our HAELO Phase 3 Trial Design for #hereditaryangioedema. Be sure to stop by our booth to learn more about Intellia.

$NTLA announces recent company progress and first quarter financial results. Read more: ir.intelliatx.com/news-releases/…

This week, Intellia will be in Las Vegas at the Bank of America Securities Healthcare Conference. Join us as our Chief Financial Officer, Ed Dulac, takes part in a fireside chat: bofa.veracast.com/webcasts/bofa/…

Intellia is looking forward to attending the HFA/European Society of Cardiology annual Heart Failure Congress in Belgrade, Serbia. HCPs: tune into our presentation about our approach in hereditary & wild-type #ATTR with cardiomyopathy on May 17: esc365.escardio.org/Heart-Failure/… #HeartFailure2025

At Intellia, our commitment to the patient community runs deep. This #HAEDay we honor the strength, resilience and stories of those living with #hereditaryangioedema. Together, we can raise awareness and advocate for a better and brighter future. Here are some of our favorite

Intellia announces positive two-year follow-up data from its ongoing Phase 1 study in #ATTR with polyneuropathy at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh (ir.intelliatx.com/news-releases/…). HCPs: be sure to catch our oral and poster presentation and stop by our booth to meet our

Intellia’s SVP, Technical Operations, Kristy Wood, Ph.D., will be delivering a keynote at TIDES (TIDES - Informa Connect) at 10:15 a.m. PT today, titled: Realizing the Promise of #CRISPR Therapies. Join us as we dive into all things about Intellia and #geneediting. informaconnect.com/tides/speakers…

Members from Intellia management will be at the RBC Capital Markets (RBC Capital Markets) Global Healthcare Conference in New York. We look forward to connecting and sharing our vision for the future. $NTLA intelliatx.com

We are excited about this new American Heart Association initiative and look forward to supporting continued progress on ATTR-CM. Learn more: newsroom.heart.org/news/advancing… #ATTR #transthyretinamyloidosis

Our #HAE team is off to Budapest for the C1-Inhibitor Deficiency & Angioedema Workshop. HCPs: tune into our oral and poster presentations this weekend about our research and Phase 3 HAELO study design for #hereditaryangioedema. 2025.haenetworkshop.hu/program/index.…

Tomorrow, Intellia Senior Director, Yong Zhang, Ph.D., will take the stage at the 7th Allogeneic Cell Therapies Summit in Boston, where he will discuss Intellia’s allogeneic platform as an approach to #celltherapy. intelliatx.com

We’re excited to share Intellia will present positive three-year data from our Phase 1 trial in #hereditaryangioedema at today’s EAACI Congress and that our global Phase 3 HAELO trial has concluded screening ahead of schedule. Read the press release: ir.intelliatx.com/news-releases/…